PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1417
https://www.valueinhealthjournal.com/article/S1098-3015(11)02979-2/fulltext
Title :
PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02979-2&doi=10.1016/j.jval.2011.08.1417
First page :
A492
Section Title :
Respiratory-Related Disorders
Open access? :
No
Section Order :
1369